JMKX003801

JMKX003801 is a novel small molecule antibacterial drug developed by Jemincare for the treatment of infections caused by Gram-negative bacteria, including those resistant to carbapenems. It is currently in phase I clinical trials in China, where it is being evaluated for safety, tolerability, and pharmacokinetics in healthy adult volunteers. The precise mechanism of action has not been disclosed but preclinical studies suggest it possesses a broad antibacterial spectrum and can overcome carbapenem resistance[1][2][5]. The drug is administered intravenously. Preclinical data indicate activity against major Gram-negative pathogens such as Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumannii, and Pseudomonas aeruginosa with demonstrated efficacy against carbapenem-resistant strains[5]. The exact molecular target or pathway remains undisclosed.